Panacea Global Presents its Cancer Diagnostic Technology at the World Cancer Congress in Melbourne,
Mon, 08 Dec 2014
Toronto, Ontario (December 4, 2014) – Panacea Global, Inc. ("Panacea") (OTCBB: PANG) a biotechnology company focused on the discovery, development and commercialization of diagnostic products for the management of cancer will present its diagnostics technology based on a novel biomarker during the World Cancer Congress organized by UICC this week in Melbourne, Australia.
Chaired by Dr. Mahmood Moshiri and Haleh Samimi, Panacea’s technology will be presented in five separate presentations during a session titled “Early and accurate diagnosis of Cancer, moving towards a solution” hosted by Sunnybrook Research Institute, Panacea Global Inc. and Proteus Imaging Canada Inc. The session’s chairman and the CEO of Panacea Global Inc, Dr. Mahmood Moshiri commented: “This session is a great example of some of the academic and industry collaborations that Panacea is involved in globally. The session is also a great opportunity for Panacea to present its technology and the significance of its novel biomarker (HAAH) to key opinion leaders attending the World Cancer Congress and the World Cancer Leaders’ Summit, UICC, 2014”.
The session also includes the below presentations:
1. Academic-Industrial collaborations as a platform for developing novel cancer diagnostics presented by :David Andrews, Sunnybrook Research Institute (Canada)
2. Highly sensitive serum-based cancer diagnostics; a solution in the developing world presented by: Kiarash Moshiri, Poznan University of Medical Sciences (Poland)
3. Early cancer diagnosis using a new bio-marker (HAAH) reduces time-to-treatment, patient anxiety and health care costs. Presented by: Omid Khojasteh, Princess Margaret Hospital Australia (Australia)
4. Progress in cancer diagnosis through targeted imaging
Presented by: Ladan Shariat, Proteus Imaging Inc. (Canada)
5. Correlating HAAH expression with the angiogenic and lymphangiogenic response Presented by: Dan Dumont, Sunnybrook Research Institute (Canada)
About Panacea Global
Panacea Global is a biotechnology company focused on the development and commercialization of diagnostic products for the management of cancer. Panacea has developed an accurate, timely, cost effective and non-invasive early cancer detection test to increase the quality of life of cancer patients and ultimately saving lives. Panacea’s test is based on the detection of the human aspartyl (asparaginyl) β-hydroxylase (HAAH), a novel biomarker expressed in malignant cancer cells in patients’ blood samples. Panacea Global has the exclusive worldwide (excluding the USA) rights to HAAH-based cancer tests. More information about Panacea Global (OTCBB: PANG) is available at www.panaceaglobalinc.com.
About the UICC
Union for International Cancer Control (UICC) is a membership organization that exists to help the global health community accelerate the fight against cancer. Founded in 1933 and based in Geneva, UICC’s growing membership of over 800 organizations across 155 countries, features the world’s major cancer societies, ministries of health, research institutes and patient groups. Together with its members, key partners, the World Health Organization, World Economic Forum and others, UICC is tackling the growing cancer crisis on a global scale.
About the World Cancer Congress
A biennial event, the World Cancer Congress serves as a platform for discourse and advocacy as well as learning and sharing opportunity for our members and partners around the world. Convening and engaging cancer control experts and leaders in global health under one roof is essential to find solutions and actions to reduce the impact of cancer on communities around the world. The 2014 World Cancer Congress theme Joining Forces - Accelerating Progress will emphasize the impact that can be realized by consistently and energetically applying what we know, rather than waiting for possible future "breakthroughs" to change the landscape. This will be discussed across a variety of economic and cultural contexts.
Certain information contained in this document may include "forward-looking information". Without limiting the foregoing, the information and any forward-looking information may include statements regarding projects, costs, objectives and future returns of the Company or hypotheses underlying these items. In this document, words such as "may", "would", "could", "will", "likely", "believe", "expect", "anticipate", "intend", "plan", "estimate" and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. Forward-looking statements and information are based on information available at the time and/or the Company management's good-faith beliefs with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company's control. The Company does not intend, nor does it undertake, any obligation to update or revise any forward-looking information or statements contained in this document to reflect subsequent information, events or circumstances or otherwise, except as required by applicable laws.